1-10 of 10
Deborah A. Tweddle
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1374: Preclinical investigation of ATR inhibition alone and in combination with PARP inhibition in high risk neuroblastoma

Harriet E. Southgate, Lindi Chen, Nicola J. Curtin, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1374.
DOI: https://doi.org/10.1158/1538-7445.AM2020-1374
Published: 15 August 2020
View article
Journal Articles

Abstract LB-300: In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma

Lindi Chen, Fabio Pastorino, Philip Berry, Jennifer Bonner, Katrina Wood, Gareth Veal, Mirco Ponzoni, John Lunec, David R. Newell, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): LB-300.
DOI: https://doi.org/10.1158/1538-7445.AM2017-LB-300
Published: 01 July 2017
View article
Journal Articles

Abstract 1618: Carboplatin therapeutic monitoring in preterm and full-term neonates

Gareth J. Veal, Julie Errington, James Hayden, David Hobin, Dermot Murphy, Rachel A. Dommett, Deborah A. Tweddle, Helen Jenkinson, Susan Picton
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1618.
DOI: https://doi.org/10.1158/1538-7445.AM2015-1618
Published: 01 August 2015
View article
Journal Articles

Abstract 565: An investigation into the potential therapeutic benefit of targeting Skp2 in neuroblastoma.

Laura Evans, Elaine Willmore, Deborah A. Tweddle, David R. Newell
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 565.
DOI: https://doi.org/10.1158/1538-7445.AM2013-565
Published: 15 April 2013
View article
Journal Articles

Abstract 612: MDMX expression is linked with MYCN amplification or expression in neuroblastoma, and sensitizes cells to MDM2-p53 antagonists

Laura D. Gamble, Deborah A. Tweddle, John Lunec
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 612.
DOI: https://doi.org/10.1158/1538-7445.AM2011-612
Published: 15 April 2011
View article
Journal Articles

p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma

Lindi Chen, Nunzio Iraci, Samuele Gherardi, Laura D. Gamble, Katrina M. Wood, Giovanni Perini, John Lunec, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2010) 70 (4): 1377–1388.
DOI: https://doi.org/10.1158/0008-5472.CAN-09-2598
Published: 14 February 2010
View article
PDF
Includes: Supplementary data
Journal Articles

Increased Frequency of Aberrations in the p53/MDM2/p14ARF Pathway in Neuroblastoma Cell Lines Established at Relapse

Jane Carr, Emma Bell, Andrew D.J. Pearson, Ursula R. Kees, Helen Beris, John Lunec, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2006) 66 (4): 2138–2145.
DOI: https://doi.org/10.1158/0008-5472.CAN-05-2623
Published: 17 February 2006
View article
PDF
Journal Articles

Comparison between MYCN status as a determinant of in vitro cellular chemosensitivity and clinical response to chemotherapy in human neuroblastoma

Xiaohong Lu, Deborah A. Tweddle, Andrew D. J. Pearson, John Lunec
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 691.
Published: 01 May 2005
View article
Journal Articles

Aberrations of the p53/p14ARF/MDM2 pathway in neuroblastoma cell lines derived from progressive and/or relapsed tumours

Jane Carr, Andrew D. J. Pearson, Ursula R. Kees, John Lunec, Deborah A. Tweddle
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 687–688.
Published: 01 May 2005
View article
Journal Articles

Evidence for the Development of p53 Mutations after Cytotoxic Therapy in a Neuroblastoma Cell Line

Deborah A. Tweddle, Archie J. Malcolm, Nick Bown, Andrew D. J. Pearson, John Lunec
Journal: Cancer Research
Cancer Res (2001) 61 (1): 8–13.
Published: 01 January 2001
View article